Literature DB >> 20881009

TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling.

Vincent M Paulino1, Zhongbo Yang, Jean Kloss, Matthew J Ennis, Brock A Armstrong, Joseph C Loftus, Nhan L Tran.   

Abstract

A critical problem in the treatment of malignant gliomas is the extensive infiltration of individual tumor cells into adjacent brain tissues. This invasive phenotype severely limits all current therapies, and to date, no treatment is available to control the spread of this disease. Members of the tumor necrosis factor (TNF) ligand superfamily and their cognate receptors regulate various cellular responses including proliferation, migration, differentiation, and apoptosis. Specifically, the TNFRSF19/TROY gene encodes a type I cell surface receptor that is expressed on migrating or proliferating progenitor cells of the hippocampus, thalamus, and cerebral cortex. Here, we show that levels of TROY mRNA expression directly correlate with increasing glial tumor grade. Among malignant gliomas, TROY expression correlates inversely with overall patient survival. In addition, we show that TROY overexpression in glioma cells activates Rac1 signaling in a Pyk2-dependent manner to drive glioma cell invasion and migration. Pyk2 coimmunoprecipitates with the TROY receptor, and depletion of Pyk2 expression by short hairpin RNA interference oligonucleotides inhibits TROY-induced Rac1 activation and subsequent cellular migration. These findings position aberrant expression and/or signaling by TROY as a contributor, and possibly as a driver, of the malignant dispersion of glioma cells. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20881009      PMCID: PMC3092528          DOI: 10.1158/1541-7786.MCR-10-0334

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  58 in total

1.  Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines.

Authors:  Tae-Young Jung; Shin Jung; Hyang-Hwa Ryu; Young-Il Jeong; Yong-Hao Jin; Shu-Guang Jin; In-Young Kim; Sam-Suk Kang; Hyung-Seok Kim
Journal:  J Neurosurg       Date:  2008-08       Impact factor: 5.115

2.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

3.  A Pyk2-Vav1 complex is recruited to beta3-adhesion sites to initiate Rho activation.

Authors:  Chunlei Gao; Scott D Blystone
Journal:  Biochem J       Date:  2009-04-28       Impact factor: 3.857

4.  The Pyk2 FERM domain as a target to inhibit glioma migration.

Authors:  Joseph C Loftus; Zhongbo Yang; Nhan L Tran; Jean Kloss; Carole Viso; Michael E Berens; Christopher A Lipinski
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

Review 5.  Sensing invasion: cell surface receptors driving spreading of glioblastoma.

Authors:  Marcin Teodorczyk; Ana Martin-Villalba
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

6.  Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts.

Authors:  Christopher A Lipinski; Nhan L Tran; Carole Viso; Jean Kloss; Zhongbo Yang; Michael E Berens; Joseph C Loftus
Journal:  J Neurooncol       Date:  2008-07-22       Impact factor: 4.130

7.  Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression.

Authors:  Marie Le Mercier; Shannon Fortin; Véronique Mathieu; Isabelle Roland; Sabine Spiegl-Kreinecker; Benjamin Haibe-Kains; Gianluca Bontempi; Christine Decaestecker; Walter Berger; Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

8.  Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation.

Authors:  Christopher A Lipinski; Nhan L Tran; Curtis Bay; Jean Kloss; Wendy S McDonough; Christian Beaudry; Michael E Berens; Joseph C Loftus
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

9.  The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma.

Authors:  Bodour Salhia; Nhan L Tran; Amanda Chan; Amparo Wolf; Mitsutoshi Nakada; Fiona Rutka; Matthew Ennis; Wendy S McDonough; Michael E Berens; Marc Symons; James T Rutka
Journal:  Am J Pathol       Date:  2008-11-13       Impact factor: 4.307

10.  Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor.

Authors:  LiMei Wang; Jennifer J Rahn; XueQing Lun; Beichen Sun; John J P Kelly; Samuel Weiss; Stephen M Robbins; Peter A Forsyth; Donna L Senger
Journal:  PLoS Biol       Date:  2008-11-25       Impact factor: 8.029

View more
  40 in total

1.  TROY interacts with Rho guanine nucleotide dissociation inhibitor α (RhoGDIα) to mediate Nogo-induced inhibition of neurite outgrowth.

Authors:  Yan Lu; Xiujie Liu; Jianfeng Zhou; Aijun Huang; Jiazhen Zhou; Cheng He
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

2.  Correlation of perfusion parameters with genes related to angiogenesis regulation in glioblastoma: a feasibility study.

Authors:  R Jain; L Poisson; J Narang; L Scarpace; M L Rosenblum; S Rempel; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

3.  Inhibition of TROY promotes OPC differentiation and increases therapeutic efficacy of OPC graft for spinal cord injury.

Authors:  Liang Sun; Shengliang Liu; Qi Sun; Zhuying Li; Fengyan Xu; Chunmei Hou; Toshihide Harada; Ming Chu; Kun Xu; Xiaoling Feng; Yongshun Duan; Yafang Zhang; Shuliang Wu
Journal:  Stem Cells Dev       Date:  2014-06-16       Impact factor: 3.272

Review 4.  p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis.

Authors:  Paschalis Theotokis; Nikolaos Grigoriadis
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

5.  Bergamottin, a natural furanocoumarin abundantly present in grapefruit juice, suppresses the invasiveness of human glioma cells via inactivation of Rac1 signaling.

Authors:  Wenzheng Luo; Zhenyu Song; Hongwei Sun; Junxin Liang; Shanshan Zhao
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

6.  Novel cryo-imaging of the glioma tumor microenvironment reveals migration and dispersal pathways in vivid three-dimensional detail.

Authors:  Susan M Burden-Gulley; Mohammed Q Qutaish; Kristin E Sullivant; Hong Lu; Jing Wang; Sonya E L Craig; James P Basilion; David L Wilson; Susann M Brady-Kalnay
Journal:  Cancer Res       Date:  2011-08-23       Impact factor: 12.701

7.  Troy/TNFRSF19 marks epithelial progenitor cells during mouse kidney development that continue to contribute to turnover in adult kidney.

Authors:  Frans Schutgens; Maarten B Rookmaaker; Francis Blokzijl; Ruben van Boxtel; Robert Vries; Edwin Cuppen; Marianne C Verhaar; Hans Clevers
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-13       Impact factor: 11.205

8.  TROY is a promising prognostic biomarker in patients with colorectal cancer.

Authors:  Mitsuaki Nishioka; Yutaka Suehiro; Kouhei Sakai; Toshihiko Matsumoto; Naoko Okayama; Hidekazu Mizuno; Koji Ueno; Nobuaki Suzuki; Shinichi Hashimoto; Taro Takami; Shoichi Hazama; Hiroaki Nagano; Isao Sakaida; Takahiro Yamasaki
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

9.  A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion.

Authors:  Zonghui Ding; Alison Roos; Jean Kloss; Harshil Dhruv; Sen Peng; Patrick Pirrotte; Jennifer M Eschbacher; Nhan L Tran; Joseph C Loftus
Journal:  Mol Cancer Res       Date:  2017-11-08       Impact factor: 5.852

10.  Structural and mechanistic insights into the interaction between Pyk2 and paxillin LD motifs.

Authors:  Murugendra S Vanarotti; Darcie J Miller; Cristina D Guibao; Amanda Nourse; Jie J Zheng
Journal:  J Mol Biol       Date:  2014-08-29       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.